Cases & Deals

Cellectis completes $228 million IPO

Clients Cellectis SA

Jones Day represented Cellectis SA, a French biotechnology company that develops novel cancer treatments, in connection with its $228 million initial public offering in the United States and Nasdaq listing. BofA Merrill Lynch, Jefferies, and Piper Jaffray & Co. acted as lead underwriters for the offering.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.